TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF MEXICO SPECIFIC POLLEN ALLERGIES MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT TYPE LIFELINE CURVE 27
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.9 DBMR MARKET POSITION GRID 29
2.10 MARKET END USER COVERAGE GRID 30
2.11 VENDOR SHARE ANALYSIS 31
2.12 SECONDARY SOURCES 32
2.13 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PESTEL ANALYSIS 37
4.2 PORTERS FIVE FORCES MODEL 38
4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO- 39
4.4 INVENTION PATENT- 39
4.5 COUNTRY LEVEL ANALYSIS 40
5 REGULATIONS 42
5.1 MEXICO 42
6 MARKET OVERVIEW 46
6.1 DRIVERS 48
6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER 48
6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER 48
6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION 49
6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING 49
6.2 RESTRAINTS 50
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS 50
6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS 50
6.3 OPPORTUNITIES 51
6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION 51
6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS 51
6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING 51
6.4 CHALLENGES 52
6.4.1 INCREASE IN ABUSE POTENTIAL 52
6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW 53
7 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE 54
7.1 OVERVIEW 55
7.2 ANTIHISTAMINE 56
7.2.1 ANTIHISTAMINE, BY DRUG TYPE 57
7.2.2 LEVOCETIRIZINE 57
7.2.3 CETIRIZINE 58
7.2.4 LORATIDINE 58
7.2.5 DIPHENHYDRAMINE 58
7.2.6 CHLORPHENIRAMINE 58
7.2.7 FEXOFENADINE 59
7.3 CORTICOSTEROIDS 59
7.3.1 FLUTICASONE PROPIONATE 60
7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID 61
7.3.3 CROMOLYN SODIUM 61
7.3.4 OTHERS 61
7.4 DECONGESTANTS 62
7.4.1 DECONGESTANTS, BY DRUG TYPE 63
7.4.2 PSEUDOEPHEDRINE 63
7.4.3 PHENYLEPHRINE 63
7.4.4 OXYMETAZOLINE 64
7.4.5 OTHERS 64
7.5 ANTICHOLINERGICS 64
7.5.1 ANTICHOLINERGICS, BY DRUG TYPE 65
7.5.2 IPRATROPIUM BROMIDE 66
7.5.3 OTHERS 66
7.6 OTHERS 66
8 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS 67
8.1 OVERVIEW 68
8.2 INSTRUMENTS 69
8.2.1 IMMUNO ASSAY ANALYZER 70
8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER 71
8.3 RADIO IMMUNO ASSAY (RIA) 71
8.4 COUNTING IMMUNO ASSAY (CIA) 71
8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA) 71
8.6 FLUOROIMMNOASSAY (FIA) 72
8.7 CHEMILUMINESCENCE ASSAY 72
8.7.1 LUMINOMETERS 73
8.8 REAGENTS AND KITS 73
8.9 OTHERS 74
9 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST 75
9.1 OVERVIEW 76
9.2 IN VIVO TEST 77
9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST 77
9.2.2 SKIN PRICK 78
9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST 78
9.2.2.2 GREER PRICK 78
9.2.3 THE STELLAR POINT 79
9.2.4 PHAZET 79
9.2.5 BIFURCATED SMALLPOX VACCINATION TEST 79
9.2.6 23G INTRAVENOUS NEEDLE 80
9.2.7 OTHERS 80
9.2.8 PATCH TEST 80
9.2.9 INTRADERMAL TEST 80
9.3 IN VITRO TEST 81
9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST 81
9.3.2 SERUM SPECIFIC IGE ASSAY 82
9.3.3 TOTAL IGE ASSAY 82
9.3.4 BASOPHIL ACTIVATION TEST 83
10 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY END USER 84
10.1 OVERVIEW 85
10.2 HOSPITALS 86
10.3 DIAGNOSTICS LABORATORIES 86
10.4 ACADEMIC AND RESEARCH INSTITUTES 87
10.5 OTHERS 88
11 MEXICO SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL 89
11.1 OVERVIEW 90
11.2 DIRECT TENDER 91
11.3 RETAIL SALES 91
11.3.1 RETAIL SALES, BY TYPE 92
11.3.2 HOSPITAL PHARMACY 92
11.3.3 RETAIL PHARMACY 92
11.3.4 ONLINE PHARMACY 93
12 MEXICO SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE 94
12.1 COMPANY SHARE ANALYSIS: MEXICO SPECIFIC POLLEN ALLERGIES MARKET 94
13 SWOT ANALYSIS 95
14 COMPANY PROFILE 96
14.1 GLAXOSMITHKLINE PLC 96
14.1.1 COMPANY SNAPSHOT 96
14.1.2 REVENUE ANALYSIS 96
14.1.3 PRODUCT PORTFOLIO 97
14.1.4 RECENT DEVELOPMENTS 97
14.2 JOHNSON & JOHNSON SERVICES, INC 98
14.2.1 COMPANY SNAPSHOT 98
14.2.2 REVENUE ANALYSIS 98
14.2.3 PRODUCT PORTFOLIO 99
14.2.4 RECENT DEVELOPMENTS 99
14.3 PERRIGO COMPANY PLC 100
14.3.1 COMPANY SNAPSHOT 100
14.3.2 REVENUE ANALYSIS 100
14.3.3 PRODUCT PORTFOLIO 101
14.3.4 RECENT DEVELOPMENTS 101
14.4 SIEMENS HEALTHCARE GMBH 102
14.4.1 COMPANY SNAPSHOT 102
14.4.2 REVENUE ANALYSIS 102
14.4.3 PRODUCT PORTFOLIO 103
14.4.4 RECENT DEVELOPMENTS 103
14.5 THERMO FISHER SCIENTIFIC INC. 104
14.5.1 COMPANY SNAPSHOT 104
14.5.2 REVENUE ANALYSIS 104
14.5.3 PRODUCT PORTFOLIO 105
14.5.4 RECENT DEVELOPMENT 105
14.6 BAYER AG 106
14.6.1 COMPANY SNAPSHOT 106
14.6.2 REVENUE ANALYSIS 106
14.6.3 PRODUCT PORTFOLIO 107
14.6.4 RECENT DEVELOPMENT 107
14.7 ALCON INC. 108
14.7.1 COMPANY SNAPSHOT 108
14.7.2 REVENUE ANALYSIS 108
14.7.3 PRODUCT PORTFOLIO 109
14.7.4 RECENT DEVELOPMENTS 109
14.8 BIOMRIEUX, SA. 110
14.8.1 COMPANY SNAPSHOT 110
14.8.2 REVENUE ANALYSIS 110
14.8.3 PRODUCT PORTFOLIO 111
14.8.4 RECENT DEVELOPMENTS 111
14.9 CINFA LABORATORIES 112
14.9.1 COMPANY SNAPSHOT 112
14.9.2 PRODUCT PORTFOLIO 112
14.9.3 RECENT DEVELOPMENT 112
14.10 CIRCASSIA 113
14.10.1 COMPANY SNAPSHOT 113
14.10.2 REVENUE ANALYSIS 113
14.10.3 PRODUCT PORTFOLIO 114
14.10.4 RECENT DEVELOPMENTS 114
14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 115
14.11.1 COMPANY SNAPSHOT 115
14.11.2 PRODUCT PORTFOLIO 115
14.11.3 RECENT DEVELOPMENTS 116
14.12 LINCOLN DIAGNOSTICS, INC. 117
14.12.1 COMPANY SNAPSHOT 117
14.12.2 PRODUCT PORTFOLIO 117
14.12.3 RECENT DEVELOPMENTS 117
14.13 MINARIS MEDICAL AMERICA, INC. 118
14.13.1 COMPANY SNAPSHOT 118
14.13.2 PRODUCT PORTFOLIO 118
14.13.3 RECENT DEVELOPMENTS 118
14.14 PRESTIGE CONSUMER HEALTHCARE INC. 119
14.14.1 COMPANY SNAPSHOT 119
14.14.2 REVENUE ANALYSIS 119
14.14.3 PRODUCT PORTFOLIO 120
14.14.4 RECENT DEVELOPMENT 120
14.15 QUEST DIAGNOSTICS INCORPORATED 121
14.15.1 COMPANY SNAPSHOT 121
14.15.2 REVENUE ANALYSIS 121
14.15.3 PRODUCT PORTFOLIO 122
14.15.4 RECENT DEVELOPMENT 122
14.16 SANOFI 123
14.16.1 COMPANY SNAPSHOT 123
14.16.2 REVENUE ANALYSIS 123
14.16.3 PRODUCT PORTFOLIO 124
14.16.4 RECENT DEVELOPMENTS 124
15 QUESTIONNAIRE 125
16 RELATED REPORTS 128

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.